DRUG THERAPY PROBLEMS DURING PALLIATIVE ONCOLOGY CARE
https://doi.org/10.17650/2220-3478-2014-0-3-39-43
Abstract
Introduction. Palliative care for oncological patients requires dealing with multiple disease symptoms and requires multi-drug therapy. The search for wide-spectre drugs which can affect different pathological pathways is a pressing matter.
Methods. The effect of hydralazine sulfate on life quality of 63 palliative care oncological patients ECOG > 3, who stopped all specific therapy was investigated.
Results. Positive correlation between hydralazine sulfate use and dose of analgetics was observed, as well as reduction of need for symptomatic therapy. The median daily use of tramadol slightly increased from 263.5 ± 4.7 to 317.2 ± 3.4 mg. In 19.4 % patients after 1 month of hydralazine sulfate therapy pain was reduced to “low” and tramadol was cancelled. Decrease in symptomatic therapy need was observed in 85 % patients.
Conslusion. Use of hydralazine sulfate in palliative oncological care improves treatment and life quality.
About the Authors
A. V. Palekhov
Palliative Care Center, Stavropol Territorial Clinical Oncology Dispensary
Deparment of Oncology and Radiotherapy with Course of Continuing Professional Education,
Stavropol State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
V. M. Danilian
Deparment of Oncology and Radiotherapy with Course of Continuing Professional Education,
Stavropol State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Здравоохранение в России. 2013. Стат. сб-к. М.: Росстат, 2013. 380 с.
2. Foley K.M., Wagner J.L., Joranson D.E., Gelband H. Pain control for people with cancer and AIDS. In: Disease control priorities in developing countries. New York: Oxford University Press, 2006. P. 981–994.
3. Палехов А.В. Наркотические лекарственные средства в России. Врач 2013;4:2–5.
4. Филов В.А., Гершанович М.Л., Стуков А.Н. Сегидрин – препарат для лечения онкологических больных. СПб., 2002. 20 с.
5. Филов В.А. Сегидрин – противоопухолевый препарат нового типа. Вопросы онкологии 1994;40(1–3):3–14.
6. Филов В.А., Данова Л.А., Гершанович М.Л. и др. Результаты клинического изучения препарата гидразинсульфат. Вопросы онкологии 1990;36(6):721–6.
7. Брюзгин В.В., Платинский Л.В. Опыт применения сегидрина при лечении онкологических больных в амбулаторных условиях. Фарматека 2006;18:81–6.
8. Филов В.А., Гершанович М.Л., Ивин Б.А. и др. Лечение первичных опухолей головного мозга сегидрином. Вопросы онкологии 1994;40(7–12):332–6.
9. Зайдинер Б.М. Сегидрин в паллиативной онкологии. Фарматека 2003;14(77):66–70.
10. Новиков Г.А., Прохоров Б.М., Вайсман М.А. и др. Возможности сегидрина в улучшениии качества жизни онкологических больных с хронической болью. Паллиативная медицина и реабилитация 2004;3:35–7.
Review
Views:
667
Email this article 